采用不同剂量重组人生长激素治疗特发性矮小症的效果分析  

Effect of Different Doses of Recombinant Human Growth Hormone in Treatment of Idiopathic Short Stature

作　　者：曾远辉[1] ZENG Yuanhui(Foshan City First People’s Hospital,Guangdong Foshan 528000,Chin)

机构地区：[1]佛山市第一人民医院,广东佛山528000

出　　处：《广东微量元素科学》2017年第5期52-55,共4页Trace Elements Science

摘　　要：目的探讨和分析采用不同剂量重组人生长激素治疗特发性矮小症的效果。方法选取2013年11月至2015年11月期间在佛山市第一人民医院接受临床治疗的60例特发性矮小症患儿作为研究对象,按照重组人生长激素的使用剂量不同分为3组,每组分别有20例患儿,对实验1组患儿每周给予0.26 mg/kg,对实验2组患儿每周给予0.35 mg/kg,对实验3组患儿每周给予0.41 mg/kg,分析3组患儿的效果。结果实验2组、实验3组治疗之后的ΔHt SDS、GV、IGF-1、IGFBP-3及患儿家长对治疗效果的总满意度与实验1组相比较,组间差异明显(P<0.05)。结论每周应用O.35 mg/kg和0.41 mg/kg的重组人生长激素治疗特发性矮小症患儿的临床效果较佳。Objective To investigate and analyze the effect of different doses of recombinant human growth hormone in the treatment of idiopathic short stature. Methods 60 cases of idiopathic short stature children, accepted in our hospital from November 2013 to November 2015 were chosen as the research object, and were divided into three groups according to the use of recombinant human growth hormone dose, 20 cases in each group. Group 1 were given 0. 26 mg/kg every week, while group 2 were given 0. 35 mg/kg every week, and group 3 were given 0. 41 mg/kg every week. The effect of the three groups were compared. Results The level of AHtSDS, GV, IGF - 1 , IGFBP - 3 and satisfaction degree of Group 2 and Group 3 had significant difference between that of Group 1 （ P 〈 0. 05 ） . Conclusion The application of recombinant human growth hormone （0. 35 mg/kg or 0. 41 mg/ kg） has better effect in the treatment of idiopathic short stature.

关 键 词：重组人生长激素 剂量 特发性矮小症 效果 

分 类 号：R725.8[医药卫生—儿科]